Recently, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have been successful in clinical use in regulating glucose metabolism in diabetes mellitus patients apart from other therapies like insulin, sulfonylureas, biguanides, meglitinides, thiazolidinediones, and alpha-glucosidase inhibitors [10]. The gene discussed is DPP4; the disease is diabetes mellitus.